文献速递心脑血管急症重症综合管理与镇静镇痛

颞肌体积丢失与蛛网膜下腔出血患者不良预后相关:一项观察性队列研究

The Loss of Temporal Muscle Volume is Associated with Poor Outcome in Patients with Subarachnoid Hemorrhage: An Observational Cohort Study.
PubMed 文献 · Neurocrit Care · 2023-06-12
一句话结论自发性蛛网膜下腔出血后颞肌体积每周平均减少7.9%,最大丢失百分比与3个月不良预后独立相关(HR 1.027/1%丢失,95%CI 1.003–1.051)。

该研究为前瞻性收集数据的回顾性分析,纳入110例连续的自发性蛛网膜下腔出血患者,在入院时及每周±2天通过头部CT评估颞肌体积。基线颞肌体积18.5±0.78 cm3,随时间显著下降(p<0.001),平均每周减少7.9%。疾病严重程度(p=0.002)、脑积水(p=0.020)、肺炎(p=0.032)和血流感染(p=0.015)与更显著的肌肉体积丢失相关。不良功能预后(3个月改良Rankin量表评分≥3分)患者ICU期间最大肌肉体积丢失更大(-32.2%±2.5% vs -22.7%±2.5%,p=0.008),且每1%最大肌肉体积丢失的不良预后风险比HR为1.027(95%CI 1.003–1.051)。

要点

  • 自发性蛛网膜下腔出血后颞肌体积随时间显著下降(p<0.001),平均每周减少7.9%。
  • 疾病严重程度(p=0.002)、脑积水(p=0.020)、肺炎(p=0.032)和血流感染(p=0.015)与更显著的肌肉体积丢失相关。
  • 不良功能预后(3个月mRS≥3)患者最大肌肉体积丢失为-32.2%±2.5%,显著大于良好预后患者的-22.7%±2.5%(p=0.008)。
  • 每1%最大肌肉体积丢失对应不良预后的风险比HR为1.027(95%CI 1.003–1.051)。
  • 常规头部CT可评估颞肌体积,可能作为肌肉消耗和预后判断的生物标志物。

适用人群与场景

  • 连续的自发性蛛网膜下腔出血患者,中位Hunt & Hess评分4分(四分位间距3-5),中位年龄61岁(50-70),女性73例(66%)。

诊断标准与关键阈值

  • 不良功能预后定义为3个月改良Rankin量表评分≥3分。
  • 颞肌体积在入院时及每周±2天(时间窗±2天)通过头部CT评估,尽可能双侧评估并取平均值用于分析。

研究设计与关键结果

  • 研究类型:前瞻性收集数据的回顾性分析;样本量110例;人群为自发性蛛网膜下腔出血患者。
  • 基线颞肌体积为18.5±0.78 cm3,随时间显著下降(p<0.001),平均每周减少7.9%。
  • 疾病严重程度(p=0.002)、脑积水(p=0.020)、肺炎(p=0.032)和血流感染(p=0.015)与更显著的肌肉体积丢失相关。
  • 不良功能预后患者与良好预后患者相比,蛛网膜下腔出血后第2周和第3周肌肉体积更小(p=0.025)。
  • ICU期间最大肌肉体积丢失在不良功能预后患者中更大(-32.2%±2.5% vs -22.7%±2.5%,p=0.008)。
  • 每1%最大肌肉体积丢失的不良预后风险比HR为1.027(95%CI 1.003–1.051)。

证据类型、等级与局限

  • 证据类型:观察性队列研究(前瞻性收集数据的回顾性分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,颞肌体积易于在常规头部CT上评估,可能作为肌肉消耗和预后判断的生物标志物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Intensive care unit (ICU) acquired weakness is a major contributor to poor functional outcome of ICU patients. Quantification of temporal muscle volume assessed on routine computed tomography (CT) scans may serve as a biomarker for muscle wasting in patients suffering from acute brain injury.

METHODS: This is a retrospective analysis of prospectively collected data. Temporal muscle volume was assessed on head CT scans of consecutive patients with spontaneous subarachnoid hemorrhage within prespecified time frames (on admission, then weekly ± 2 days). Whenever possible, temporal muscle volume was assessed bilaterally and averaged for the analysis. Poor functional outcome was defined as a 3-month modified Rankin Scale Score ≥ 3. Statistical analysis was performed using generalized estimating equations to handle repeated measurements within individuals.

RESULTS: The analysis comprised 110 patients with a median Hunt & Hess score of 4 (interquartile range 3-5). Median age was 61 (50-70) years, 73 patients (66%) were women. Baseline temporal muscle volume was 18.5 ± 0.78 cm3 and significantly decreased over time (p < 0.001) by a mean of 7.9% per week. Higher disease severity (p = 0.002), hydrocephalus (p = 0.020), pneumonia (p = 0.032), and bloodstream infection (p = 0.015) were associated with more pronounced muscle volume loss. Patients with poor functional outcome had smaller muscle volumes 2 and 3 weeks after subarachnoid hemorrhage compared with those with good outcome (p = 0.025). The maximum muscle volume loss during ICU stay was greater in patients with poor functional outcome (- 32.2% ± 2.5% vs. - 22.7% ± 2.5%, p = 0.008). The hazard ratio for poor functional outcome was 1.027 (95% confidence interval 1.003-1.051) per percent of maximum muscle volume loss.

CONCLUSIONS: Temporal muscle volume, which is easily assessable on routine head CT scans, progressively decreases during the ICU stay after spontaneous subarachnoid hemorrhage. Because of its association with disease severity and functional outcome, it may serve as a biomarker for muscle wasting and outcome prognostication.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Kofler M, Reitmeir P, Glodny B, et al. The Loss of Temporal Muscle Volume is Associated with Poor Outcome in Patients with Subarachnoid Hemorrhage: An Observational Cohort Study. Neurocrit Care. 2023. PMID: 37308731. doi:10.1007/s12028-023-01751-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。